ResearcherFirst Affiliated Hospital of Dalian Medical UniversityActive in the last 2 years

Xing Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9145-4769; OpenAlex author ID A5100358650. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis. Last author DOI 10.1016/j.isci.2024.111343 ↗
Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment… First author DOI 10.1016/j.ejmech.2022.114607 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Zhang · 1 shared paper, 2024 · strength 0.24
- Paper Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis. DOI 10.1016/j.isci.2024.111343 ↗
Xu Zheng · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Xiaodong Ma · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Changyuan Wang · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗
Yanxia Li · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.